MERCK CMV MK-8228 LET (Kidney Transplant) - Clinical Trial
Email to Participate
julie.narcisi@duke.edu
What is the Purpose of this Study?
If you choose to join this study, you will:
- Be randomized (like flipping a coin) to Group 1 or Group 2
-- Group 1 will get the study drug, Letermovir (LET)
-- Group 2 will get the standard of care medicine, Valganciclovir (VGCV)
- Both groups will also be asked to give blood
What is the Condition Being Studied?
Kidney Transplant
Who Can Participate in the Study?
Adults who:
- Have had or will have a kidney transplant within 7 days of signing up for the study
Age Group
Adults
What is Involved?
We are doing this study to learn more about the study drug (Letermovir) and how it can help keep people from getting Human Cytomegalovirus (CMV) disease.
Study Details
Full Title
A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients
Principal Investigator
Kidney/Pancreas Transplant Surgeon
Protocol Number
IRB:
PRO00090050
NCT:
NCT03443869
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Email julie.narcisi@duke.edu